Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation

Ruutu, T; van Biezen, A; Hertenstein, B; Henseler, A; Garderet, L; Passweg, J; Mohty, M; Sureda, A; Niederwieser, D; Gratwohl, A; de Witte, T
November 2012
Bone Marrow Transplantation;Nov2012, Vol. 47 Issue 11, p1459
Academic Journal
Recommendations on indications for allogeneic haematopoietic SCT have been presented, but transplantation techniques remain poorly standardized. Pre-transplant risk factors are well defined, and reported outcomes vary markedly among patients with similar risk characteristics. It would be of importance to know the impact of differences in treatment procedures. To study properly the different components of allogeneic transplantation, standardization of at least some central procedures would be needed. As the first step, the European Group for Blood and Marrow Transplantation (EBMT) performed a survey among all its 372 member centres performing allogeneic transplantations about their strategies in preventing and treating GVHD. Responses from 79 centres (21% return) from 25 countries (60% return) were received. Although some trends toward more uniform policies compared with a survey carried out 15 years earlier were observed, the present survey still showed marked variability in the GVHD prophylaxis and treatment strategies. On the basis of these findings, EBMT is developing a consensus process aiming at a standardized strategy.


Related Articles

  • Hematopoietic Stem Cell Transplantation. Gratwohl, Alois; Baldomero, Helen; Aljurf, Mahmoud; Pasquini, Marcelo C.; Bouzas, Luis Fernando; Yoshimi, Ayami; Szer, Jeff; Lipton, Jeff; Schwendener, Alvin; Gratwohl, Michael; Frauendorfer, Karl; Niederwieser, Dietger; Horowitz, Mary; Kodera, Yoshihisa // JAMA: Journal of the American Medical Association;4/28/2010, Vol. 303 Issue 16, p1617 

    The article discusses a study which investigated the current use of hematopoietic stem cell transplantation (HSCT) to assess differences in its application. Associations of macroeconomic factors with transplant rates on a global level were also explored. The study involved patients receiving...

  • Stem cell source-dependent reconstitution of FOXP3+ T cells after pediatric SCT and the association with allo-reactive disease. Reubsaet, L L; de Pagter, A P J; van Baarle, D; Keukens, L; Nanlohy, N; Sanders, E A M; Prakken, B J; Boelens, J J; de Kleer, I M // Bone Marrow Transplantation;Apr2013, Vol. 48 Issue 4, p502 

    In adult patients, regulatory CD4+FOXP3+ T cells are suggested to have a role in the control of allo-reactive disease after hematopoietic SCT (HSCT). We compared CD4+FOXP3+ T-cell reconstitution after unrelated cord blood (UCB), matched unrelated donor (MUD) and matched sibling donor (MSD) HSCT...

  • Biomarkers for the detection of graft-versus-host disease in cancer patients after bone marrow transplantation. Paczesny, Sophie // Current Biomarker Findings;2012, Vol. 2, p29 

    Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective form of tumor immunotherapy available to date, and the frequency of transplants continues to increase worldwide. However, while allogeneic HSCT can induce beneficial graft-versus-tumor (GVT) effects, the adverse...

  • Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Goldman, J M; Schmitz, N; Niethammer, D; Gratwohl, A // Bone Marrow Transplantation;1/1/98, Vol. 21 Issue 1, p1 

    In 1996, the Accreditation Sub-Committee of the EBMT published a special report summarising current practice in Europe in relation to haemopoietic stem cell transplants for haematological diseases, solid tumours and immune disorders. An updated report is presented here. The major change has been...

  • Invasive microsporidiosis in allogeneic haematopoietic SCT recipients. Ambrosioni, J.; van Delden, C.; Krause, K. H.; Bouchuiguir-Wafa, C.; Nagy, M.; Passweg, J.; Chalandon, Y. // Bone Marrow Transplantation;Jul2010, Vol. 45 Issue 7, p1249 

    The article presents a case study of a 49-year-old woman admitted for allo-hematopoietic stem cell transplantation (HSCT) from an unrelated donor human leukocyte allele (HLA) matched 9/10 to treat her Hodgkin's lymphoma (HL) 20 months prior to the admission. Treatments given to the patient...

  • Autologous blood pleurodesis for pneumothorax complicating graft-versus-host disease-related bronchiolitis obliterans. Chadwick, C.; Marven, S. M.; Vora, A. J. // Bone Marrow Transplantation;Feb2004, Vol. 33 Issue 4, p451 

    Summary:Bronchiolitis obliterans (BO) is a manifestation of chronic graft-versus-host disease (GVHD) after allogeneic haemopoietic stem cell transplantation. Complications associated with this include persistent air-leak syndromes such as pneumothorax. Many methods have been described for...

  • Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation. Hägglund, H; Remberger, M; Ringden, O // Bone Marrow Transplantation;Dec2014, Vol. 49 Issue 12, p1541 

    The article discusses the follow-up of a randomized trial in 1998 which compares intraosseous (i.o.) and i.v. transplantation of allogeneic haematopoietic stem cells. The probability of chronic graft versus host disease (GVHD) was deemed similar to both transplantation. Induction of persistent...

  • Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. Gomez, E; Duléry, R; Langlois, C; Coiteux, V; Terriou, L; Magro, L; Gauthier, J; de Berranger, E; Duhamel, A; Yakoub-Agha, I // Bone Marrow Transplantation;Dec2014, Vol. 49 Issue 12, p1492 

    In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m2 to the classical association of fludarabine, 30 mg/m2/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51...

  • Sirolimus enhances the effect of apoptotic cell infusion on hematopoietic engraftment and tolerance induction. Bonnefoy, F; Masson, E; Perruche, S; Marandin, A; Borg, C; Radlovic, A; Shipman, B; Tiberghien, P; Saas, P; Kleinclauss, F // Leukemia (08876924);Jul2008, Vol. 22 Issue 7, p1430 

    This article discusses the use of sirolimus, cyclosporin A, or mycophenolate mofetil, to prevent graft-versus-host disease (GVHD) and related toxicities in patients treated with allogeneic hematopoietic cell transplantation (AHCT). The use of these medications was combined with the intraveneous...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics